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ABSTRACT 
We report a rare case of Mycobacterium monacense isolated from the blood of a patient with carcinoma breast with an infected 
chemoport. Initial blood cultures from peripheral line and port were sterile. Repeated blood cultures signaled positive which 
showed weakly stained gram positive bacilli on smear from both the vials. Nontuberculous Mycobacterial infection and 
speciation were confirmed by real time polymerase chain reaction and sequencing. Chemoport was removed and patient 
responded to 3 drug regimen with Rifampicin, Ethambutol and Clarithromycin therapy with no recurrence at 15 month follow-
up. 
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n the past few years, rate of Nontuberculous 
Mycobacteria (NTM) detection has risen in both 
immunocompromised and immunocompetent patients 
[1]. The pathogenic role of NTM has been in doubt for 
several years. Only Mycobacterium fortuitum and M. 
chelonae were considered to be potentially responsible for 
disease [2]. In the last few years, many rapidly growing 
species that are often responsible for disease have been 
described in humans. Till date, only 5 case reports of 
isolation of M. monacense from independent clinical 
specimens have been reported [3-7]. For the first time we 
report the isolation of M. monacense from blood of patient 
with carcinoma breast, with an infected chemoport to the 
best of our knowledge.
 
CASE REPORT 
A 55 year old female underwent right modified radical 
mastectomy for carcinoma breast. Histopathological  
 
examination revealed infiltrating duct carcinoma grade 3, 
pT1N0M0, estrogen receptor negative and HER 2 neu 
positive. Subsequently, patient was planned for adjuvant 
chemotherapy and monoclonal antibody trastuzumab. 
Chemoport placement was done under standard aseptic 
precautions. Patient initially received 3 weekly and then 12 
cycles of weekly chemotherapy regime.  
She was continued on 3 weekly infusions of 
Trastuzumab (440mg). While on treatment, she presented 
with low grade fever which was treated with empirical 
antibiotics. She was non neutropenic and HIV was non 
reactive. However, she did not respond to oral antibiotics. 
The fever worsened and was now associated with chills 
and rigors; especially, when the chemoport was used for 
administration of drugs. She was then admitted for 
administration of broad spectrum intravenous antibiotics 
including Vancomycin suspecting a chemoport infection. 
I 
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She was hemodynamically stable and the chemoport site 
did not show any signs of inflammation.  
CT scans of the chest and abdomen as part of the work 
up were normal.  Initial blood cultures from peripheral line 
and from the port were sterile. She did not respond to 
antibiotics and had worsening of her fever, which was now 
associated with increasing fatigue and dry cough. Blood 
culture was repeated from both peripheral venipuncture 
and the port by BacT/ALERT® 3D (bioMérieux). Blood 
culture from port catheter signaled positive after 44 hours 
and from peripheral venipuncture site signaled positive on 
the third day. Gram stained smears from both the vials 
showed weakly stained gram positive bacilli in clusters. 
Ziehl-Neelsen staining on both the samples showed acid 
fast bacilli (AFB). The sample was sub cultured on blood 
agar, Macconkey agar and Lowenstein-Jensen (LJ) 
medium. There was growth on blood agar but not on 
Macconkey agar. It took 5 days for growth on LJ medium. 
 
Figure 1 – Dark yellow pigmented colonies on LJ medium        
 
Figure 2 – Amplification plot for NTM detection by real 
time PCR 
Colonies on LJ medium, which were incubated in dark, 
showed yellow pigmention (Fig. 1). The conventional 
biochemical tests performed showed positive results for 
growth in 4.5% sodium chloride, nitrate reductase test and 
negative results for niacin accumulation test and aryl 
sulfatase production test. Bacterial DNA extraction was 
done from dark yellow colonies of bacteria in LJ medium, 
by Dynabeads® DNA DIRECT Universal KIT (Life 
technologies). Real time polymerase chain reaction (RT-
PCR) for qualitative detection of M. tuberculosis (MTB) 
and NTM was done using RT-PCR KIT (3B BLACK 
BIO). The detection was based on amplification of region 
upstream of the 65kDa hsp probes specific for NTM 
genus.  
M. tuberculosis detection was based on primer and 
probes targeting IS61105 and MPB646 gene. The isolate 
was negative for M. tuberculosis but amplified for hsp65 
gene indicating that the isolate was positive for NTM (Fig. 
2) For speciation, PCR-based DNA sequencing of the 
isolate was done with combination of three different gene 
targets employed for accurate identification of more than 
90 different species using DNA sequencing methodology 
(SRL diagnostics, Mumbai, India). The isolate was 
confirmed as M. monacense. Antibiotic susceptibility 
testing was done following CDC guidelines by the 
standard MIC method and tested for the first line drugs 
Streptomycin, Rifampicin, Ethambutol, Isoniazide and also 
Levofloxacin, Amikacin, Cotrimoxazole, Azithromycin, 
Clarithromycin, Linezolid. 
Based on the site of infection, the treatment was 
planned for a period of one year, along with antibody 
therapy for the carcinoma (which was not 
immunosuppressive). The chemoport was removed and 
patient was started empirically on 3 drug regimen with 
Rifampicin, Ethambutol and Clarithromycin to which she 
responded. Over the next two weeks, the fever spikes came 
down and general condition improved. As the patient was 
tolerating the drugs well with no side effects, the same line 
of treatment was continued and the patient successfully 
completed the treatment. She was on follow-up for the past 
15 months with no relapse till date. 
DISCUSSION 
Nontuberculous Mycobacteria are widely distributed in the 
environment with high isolation rates worldwide. They are 
divisible into two main groups: (a) the slow growers and 
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(b) the rapid growers, according to their rate of growth on 
subculture. In India, rapidly growing Mycobacteria (RGM) 
have been associated with various clinical syndromes in 
immunocompetent and immunocompromised hosts. The 
risk factors and outcomes of RGM infection in patients 
with carcinoma have not been clearly defined. With rare 
exceptions, the pathogenic RGM are M. abscessus, M. 
chelonae and M. fortuitum [8]. 
Table 1: Reported cases of M. monacense infection 
N
o 
Article Sample  Clinical 
Indications 
Pathogenic 
Role 
1 Reischl et 
al (2006) 
bronchial 
lavage  
Lung 
carcinoma 
Uncertain 
2 Taieb et al 
(2008) 
left thumb Diabetic 
with hand 
infection 
Pathogenic  
3 Hogardt et 
al (2008) 
bronchial 
lavage  
Tuberculosis Pathogenic 
4 Therese 
KL et al 
(2011) 
sputum Tuberculosis Pathogenic 
5 Shojaei H 
et al 
(2012) 
sputum Chronic 
respiratory 
infection 
Pathogenic 
 
Mycobacterium monacense is a gram-positive, acid-
fast, non-motile, non spore forming AFB that produces 
smooth, yellow, scotochromogenic colonies within 7 days 
at 25–450C [2]. It was first reported from bronchial lavage 
in a 80-year-old patient by Reischl et al [2]. Initial reports 
could not confirm the pathogenic potential of M. 
monacense but subsequent reports confirmed the 
pathogenic role of the organism [4-8]. Till date, this is the 
first report of isolation of M. monacense from the 
chemoport. The present report suggests that M. monacense 
should be considered to be a potential human pathogen. 
The reported cases of M. monacense infection are 
summarized in Table 1. 
CONCLUSION 
To the best of our knowledge, this is the first case report of 
isolation of M. monascence associated with chemoport 
infection from India, establishing its pathogenic role. The 
condition of the patient improved on removal of the 
chemoport. The differentiation of MTB from NTM is of 
prime significance for choice of antimicrobial therapy and 
duration of treatment. 
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